A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
10/16/2026
BreakingRegulationThyroid Eye Disease
US FDA Approves Genentech’s Enspryng, the First Subcutaneous Treatment for TED
Genentech and its parent, Roche, announced Oct. 16 that the US FDA had approved Enspryng (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED). It’s the first at-home, subc...
10/16/2026
BiosimilarsBreakingEuropeRegulationRetina
Alvotech, Advanz Submit Marketing Application to EMA for High-Dose Aflibercept Biosimilar
Alvotech and partner Advanz Pharma announced Oct. 14 that they had submitted a marketing authorization application to the European Medicines Agency (EMA) for AVT29, a proposed biosimilar to Eylea (...
10/16/2026
BreakingClinical TrialPharmaRetina
Merck Sees Mixed Results at One Year in Pivotal Trial of Remigromig in DME
Merck presented one-year results from remigromig’s pivotal Phase IIb/III BRUNELLO trial at the 2026 meeting of the American Academy of Ophthalmology (AAO), held Oct. 10-12 in New Orleans, Louisiana...
10/16/2026
BreakingIndustryPharmaSurgical
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over
Bausch + Lomb announced Oct. 12 that CEO Brent Saunders would leave the company immediately, with chairman Thomas Appio taking over as interim CEO. Appio also is CEO of Bausch Health. Saunders had ...
10/16/2026
BreakingPharmaRegulationRetinaUveitis
US FDA Accepts BLA for Genentech’s Vamikibart in UME; Decision Expected by July 2027
Genentech, a member of the Roche group, reported Oct. 10 that the US FDA had accepted the biologics license application (BLA) for vamikibart, an intravitreal IL-6 inhibitor candidate for uveitic ma...
10/16/2026
BreakingCornealDeals
Visara Licenses Topical Neurotrophic Keratitis Candidate from China’s Hiteck
Visara, the ophthalmic subsidiary of NovaBridge Biosciences, announced Oct. 13 that it had licensed a topical candidate targeting neurotrophic keratitis (NK) from China’s Wuhan Hiteck Biopharma. VI...
10/16/2026
BreakingInstrumentsSingle-UseSurgical
Corza Medical Launches Expanded Single-Use Custom Packs
Corza Medical, of Boulder, Colorado, announced Oct. 10 the launch of its expanded Blink single-use custom surgical packs. The company also debuted a new automated manufacturing process for its Shar...
10/16/2026
BreakingCataractSurgical
HelpMeSee Names Former Test Pilot Doug May as President and CEO
Global nonprofit group HelpMeSee announced Oct. 1 that it had appointed Doug May as president and chief executive officer. May joined HelpMeSee in 2025 as chief operating officer. He previously wor...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.